EARLY SEPSIS DIAGNOSTICS

Strategic collaborations

For this illness, Novo Healthcare has partnered with German-based Molzym, a manufacturer committed to innovative solutions for biological research and diagnosis of infectious diseases. Molzym’s developmental efforts are particularly focused on new processes enabling and facilitating the molecular diagnosis of diseases caused by bacteria and fungi.

Molecular biological methods particularly polymerase chain reaction (PCR), are generally accepted as promising means of culture-flanking methods for early sepsis diagnosis, mostly because of its rapidity of time-to-result and independence of growth of strains.